These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 33078556)

  • 1. The Working Group for Revision of "Guidelines for the Use of Palivizumab in Japan": A Committee Report.
    Okada K; Mizuno M; Moriuchi H; Kusuda S; Morioka I; Mori M; Okamoto K; Okada K; Yoshihara S; Yamagishi H; Yokoyama U; Kubota T; Kudo K; Takagi M; Ito S; Kanamori Y; Sasahara Y
    Pediatr Int; 2020 Nov; 62(11):1223-1229. PubMed ID: 33078556
    [No Abstract]   [Full Text] [Related]  

  • 2. Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era.
    Taylor RS
    CMAJ; 2021 Apr; 193(15):E523. PubMed ID: 33846202
    [No Abstract]   [Full Text] [Related]  

  • 3. [Recommendations for palivizumab use. Update 2015].
    ; Fernández Jonusas S; Albas Maubett D; Satragno D; Cattaino A; Martin Alonso M; Rubio C; Nieto R; ; ; ; ; ; ;
    Arch Argent Pediatr; 2016 Feb; 114(1):84-8. PubMed ID: 26914078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [An update of the recommendations of the Spanish Neonatology Society for the use of palivizumab as prophylaxis for severe infections due to syncytial respiratory virus in high risk infants].
    Sánchez Luna M; Pérez Muñuzuri A; Leante Castellanos JL; Ruiz Campillo CW; Sanz López E; Benavente Fernández I; Sánchez Redondo MD; Rite Gracia S;
    An Pediatr (Engl Ed); 2019 Nov; 91(5):348-350. PubMed ID: 31585838
    [No Abstract]   [Full Text] [Related]  

  • 5. Re-evaluating the New Committee on Infectious Diseases Recommendations for Palivizumab Use in Premature Infants.
    Yogev R; Krilov LR; Fergie JE; Weiner LB
    Pediatr Infect Dis J; 2015 Sep; 34(9):958-60. PubMed ID: 26107347
    [No Abstract]   [Full Text] [Related]  

  • 6. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.
    Saji T; Nakazawa M; Harada K
    Pediatr Infect Dis J; 2008 Dec; 27(12):1108-9. PubMed ID: 18978515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospitalisations due to respiratory syncytial virus infection in children with Down syndrome before and after palivizumab recommendation in Japan.
    Okamoto K; Morio T; Nakamura Y; Hataya H; Mizuta K; Mori M
    Acta Paediatr; 2021 Apr; 110(4):1299-1306. PubMed ID: 33119906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Loss of Respiratory Syncytial Virus Seasonality and the Effects on Palivizumab Administration.
    Tan D; Goff Z; MacDonald B; Blyth CC; Foley DA
    Pediatr Infect Dis J; 2022 Sep; 41(9):e407-e408. PubMed ID: 35763694
    [No Abstract]   [Full Text] [Related]  

  • 9. Palivizumab in congenital heart disease: should international guidelines be revised?
    Geskey JM; Thomas NJ; Brummel GL
    Expert Opin Biol Ther; 2007 Nov; 7(11):1615-20. PubMed ID: 17961086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Update of recommendations on the use of palivizumab as prophylaxis in RSV infections].
    Figueras Aloy J; Carbonell Estrany X;
    An Pediatr (Barc); 2015 Mar; 82(3):199.e1-2. PubMed ID: 25453311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appropriate use of palivizumb (Synagis).
    Graham LM; Lesnick B
    Pediatr Pulmonol Suppl; 2004; 26():156-7. PubMed ID: 15029637
    [No Abstract]   [Full Text] [Related]  

  • 12. Restrictive Palivizumab Use Does Not Lead to Increased Morbidity and Mortality in Pediatric Hematopoietic Stem Cell Transplantation Patients.
    Teusink-Cross A; Davies SM; Danziger-Isakov L; El-Bietar J; Grimley MS
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1904-1906. PubMed ID: 27422147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expert consensus on palivizumab use for respiratory syncytial virus in developed countries.
    Luna MS; Manzoni P; Paes B; Baraldi E; Cossey V; Kugelman A; Chawla R; Dotta A; Rodríguez Fernández R; Resch B; Carbonell-Estrany X
    Paediatr Respir Rev; 2020 Feb; 33():35-44. PubMed ID: 31060948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevention of respiratory syncytial virus infections with palivizumab].
    Ellingsen BB; Aase SA; Øymar K
    Tidsskr Nor Laegeforen; 2003 Apr; 123(7):941-3. PubMed ID: 12737068
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of an Antimicrobial Stewardship Policy to Restrict Palivizumab Use.
    Joerger T; Chan S; Swami SK; Handy LK
    J Pediatric Infect Dis Soc; 2019 May; 8(2):189-190. PubMed ID: 29096027
    [No Abstract]   [Full Text] [Related]  

  • 16. Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates.
    Gortner L
    Klin Padiatr; 2017 Sep; 229(5):259-260. PubMed ID: 28926860
    [No Abstract]   [Full Text] [Related]  

  • 17. Infants born before 32 weeks of gestation or with respiratory disease are most likely to receive palivizumab in the Netherlands.
    Kool-Houweling LM; Penning-van Beest FJ; Bezemer ID; van Lingen RA; Herings RM
    Acta Paediatr; 2015 Sep; 104(9):927-32. PubMed ID: 26073782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palivizumab prophylaxis in preterm infants.
    Tang PK
    Lancet Respir Med; 2017 Mar; 5(3):171. PubMed ID: 28219614
    [No Abstract]   [Full Text] [Related]  

  • 19. Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab.
    Chan P; Li A; Paes B; Abraha H; Mitchell I; Lanctôt KL;
    Pediatr Infect Dis J; 2015 Dec; 34(12):e290-7. PubMed ID: 26780032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
    Resch B; Egger B; Kurath-Koller S; Urlesberger B
    Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.